

CellaVision AB completes the acquisition of exclusive rights to novel microscopy technology

CellaVision has completed the previously announced acquisition of the exclusive rights to a patent portfolio on Fourier Ptychographic Microscopy, a novel microscopy technology from Clearbridge BioPhotonics.

The acquisition gives CellaVision access and control of an interesting future technology. The Fourier Ptychography Microscopy technology has potential to be used to develop future automated microscopes, with applications in both hematology and adjacent areas. The closing took place today and will have no impact on CellaVision's earnings per share during the current financial year.

Questions on the acquisition can be addressed to:

Simon Østergaard, President and CEO, CellaVision AB,
Direct: +46 (0) 700-36 37 92
Email: simon.ostergaard@cellavision.com

Contact

Maria Morin
VP HR & Corporate Communications
Direct: +46 (0) 46 460 16 52
Mobile: +46 (0) 709 92 62 28

About Us

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company's 18 local market support organizations covering more than 40 countries. In 2020, sales were SEK 471 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

This information is information that CellaVision is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-04-20 14:17 CEST.

Attachments

[CellaVision AB completes the acquisition of exclusive rights to novel microscopy technology](#)